Pharma patent rights were at the forefront of policy discussions this year, thanks to the coronavirus pandemic. However, as IAM’s life sciences reporter Adam Houldsworth explains, they were not the only game in town
30 Dec
2020
The biggest life sciences IP stories of 2020
